製品番号: HY-N6932

Voacamine

1 Cited Publications

カスタマーレビュー

Based on 1 publication(s) in Google Scholar

Voacamine is an indole alkaloid with cannabinoid 1 (CB1) antagonistic activity. Voacamine can inhibit nuclear translocation. Voacamine is effective in enhancing the effect of Doxorubicin (HY-15142A) as it interferes with the P-glycoprotein (P-gp) function. Voacamine promotes apoptosis-independent autophagic cell death in human osteosarcoma cells. Voacamine activates mitochondrial-associated apoptosis signaling pathway and inhibition of PI3K/Akt/mTOR signaling pathway to suppress breast cancer progression. Voacamine inhibits EGFR to exert oncogenic activity against colorectal cancer.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.64%
CAS 番号: 3371-85-5
分子式: C₄₃H₅₂N₄O₅
分子量:704.90

保管条件:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Voacamine 構造式

CAS 番号: 3371-85-5

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Antibody-Drug Conjugates

One-stop solution for XDC (ADC/PDC/RDC/ApDC/FDC/ISAC/VDC/SMDC)

生物活性

製品説明

Cannabinoid Receptor アイソフォーム固有の製品をすべて表示 :

PI3K アイソフォーム固有の製品をすべて表示 :

Akt アイソフォーム固有の製品をすべて表示 :

mTOR アイソフォーム固有の製品をすべて表示 :

EGFR アイソフォーム固有の製品をすべて表示 :

体外実験

Voacamine (1.4 μM) induces a slight increase in the apoptotic fraction of 23.6% in A2780 cells^[2].
Voacamine (Compound VOA) (0-18 μM, 24-48 h) has antiproliferative activities against breast cancer cell lines (MCF-7 and 4T1)^[3].
Voacamine (0-10 μM, 24-48 h) has anti-migratory and proapoptotic effect on MCF-7 and 4T1 cells^[3].
Voacamine (1.5-5 μM) significantly diminishes the G₀/G₁ and G₂/M phase of MCF-7 and 4T1 cells^[3].
Voacamine (2.5-9 μM) collapses MMP and induces ROS production in MCF-7 and 4T1 cells^[3].
Voacamine (0-8 μM) induces inhibition of p-PI3K/p-Akt/p-mTOR pathway and interacts with PI3K protein via molecular docking simulation^[3].
Voacamine (1-10 μM, 24-72 h) results in a dose- and time-dependent reduction in the cell survival in U-2 osteosarcoma cells^[4].
Voacamine (5 μM, 24 h) shows a higher number of cells in G₁ phase than control and abundant formation of autophagosomes in U-2 osteosarcoma cells^[4].
Voacamine (0-10 μM, 24-48 h) substantially restrains the viability of CRC cell lines (CT26 and HCT116) ^[5].
Voacamine (0-10 μM) induces apoptisis via EGFR/PI3K/Akt signaling pathway in CT26 and HCT116 cells^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[3]

Cell Line:

MCF-7 and 4T1 cells
Concentration:

0, 3, 6, 9, 12, 15, 18 μM (for MCF-7); 0, 2.5, 5, 7.5, 10, 12.5, 15 μM (for 4T1)
Incubation Time:

24 and 48 h
Result:

Exhibited low toxicities against human normal breast epithelial cells.
Had the most potent cytotoxic effect on breast cancer cells for 48 h with an IC₅₀ of 0.99 and 1.42 μM for MCF-7 and 4T1 cells, respectively.
Reduced colony formation of MCF-7 and 4T1 cells.

体内実験

Voacamine (Compound VOA) (15-30 mg/kg, s.c., single dose) results in a significant reduction in the tumor volume and weight in BALB/c mice with 4T1 cells induced xenograft tumor^[3].
Voacamine (15-30 mg/kg, i.p., 2 w) suppresses the progression of xenograft colorectal tumor in BALB/c mice injected with CT26 cells^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

BALB/c mice with 4T1 cells induced xenograft tumor^[3]
Dosage:

15 and 30 mg/kg
Administration:

Subcutaneous injection (s.c.)
Result:

Increased body weights of mice whilst reduced the tumor volume and weight with 30 mg/kg dose.
Significantly downregulated levels of p-PI3K in a dose-dependent manner.

化学情報

CAS 番号 3371-85-5
性状 Solid
分子量 704.90
分子式 C₄₃H₅₂N₄O₅
Color White to off-white
SMILES

O=C(OC)[C@]1([C@@H]2[N@](CC(C[C@H]2CC)C1)CC3)C4=C3C(C=C5OC)=C(N4)C=C5[C@](C[C@@H]6[C@H](C(OC)=O)[C@H](N(C)C/C6=C/C)C7)([H])C8=C7C9=C(N8)C=CC=C9
Structure Classification
- Alkaloids
- Indole Alkaloids
Initial Source
- Plants
- other families
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (1)

All

Sort by:

Journal Impact Factor

RSC Adv

A multi-stage computational pipeline and in vitro validation for the discovery of small-molecule translation inhibitors targeting the bacterial ribosome. [Abstract]

2026 Apr 7;16(20):18359-18373. PMID: 41953617

溶剤 & 溶解度

体外:

DMSO : ≥ 100 mg/mL (141.86 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.4186 mL

7.0932 mL

14.1864 mL

5 mM

0.2837 mL

1.4186 mL

2.8373 mL

10 mM

0.1419 mL

0.7093 mL

1.4186 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (3.55 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (3.55 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (285 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Kitajima M, et al. Discovery of indole alkaloids with cannabinoid CB1 receptor antagonistic activity. Bioorg Med Chem Lett. 2011 Apr 1;21(7):1962-4. [Content Brief]

[2]. Pellegrini, E., et al., (2022). A natural product, voacamine, sensitizes paclitaxel-resistant human ovarian cancer cells. Toxicology and applied pharmacology, 434, 115816. [Content Brief]

[3]. Zuo, Y., et al., (2022). Activation of mitochondrial-associated apoptosis signaling pathway and inhibition of PI3K/Akt/mTOR signaling pathway by voacamine suppress breast cancer progression. Phytomedicine : international journal of phytotherapy and phytopharmacology, 99, 154015. [Content Brief]

[4]. Meschini, S., et al., (2008). The plant alkaloid voacamine induces apoptosis-independent autophagic cell death on both sensitive and multidrug resistant human osteosarcoma cells. Autophagy, 4(8), 1020–1033. [Content Brief]

[5]. Chen, Y., et al., (2022). Voacamine is a novel inhibitor of EGFR exerting oncogenic activity against colorectal cancer through the mitochondrial pathway. Pharmacological research, 184, 106415. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.4186 mL	7.0932 mL	14.1864 mL	35.4660 mL
	5 mM	0.2837 mL	1.4186 mL	2.8373 mL	7.0932 mL
	10 mM	0.1419 mL	0.7093 mL	1.4186 mL	3.5466 mL
	15 mM	0.0946 mL	0.4729 mL	0.9458 mL	2.3644 mL
	20 mM	0.0709 mL	0.3547 mL	0.7093 mL	1.7733 mL
	25 mM	0.0567 mL	0.2837 mL	0.5675 mL	1.4186 mL
	30 mM	0.0473 mL	0.2364 mL	0.4729 mL	1.1822 mL
	40 mM	0.0355 mL	0.1773 mL	0.3547 mL	0.8867 mL
	50 mM	0.0284 mL	0.1419 mL	0.2837 mL	0.7093 mL
	60 mM	0.0236 mL	0.1182 mL	0.2364 mL	0.5911 mL
	80 mM	0.0177 mL	0.0887 mL	0.1773 mL	0.4433 mL
	100 mM	0.0142 mL	0.0709 mL	0.1419 mL	0.3547 mL

Voacamine

1 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Voacamine

Apoptosis Compound Library

GPCR/G Protein Compound Library

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

Membrane Transporter/Ion Channel Compound Library

Neuronal Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Oxygen Sensing Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Glutamine Metabolism Compound Library

Alkaloids Library

Anti-Hepatitis C Virus Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Glucose Metabolism Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Cell Death Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Metabolite Library

Natural Product Diversity Scaffold Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

MedChemExpress（MCE）の使用を引用している文献 Voacamine

Cannabinoid Receptor アイソフォーム固有の製品をすべて表示

PI3K アイソフォーム固有の製品をすべて表示

Akt アイソフォーム固有の製品をすべて表示

mTOR アイソフォーム固有の製品をすべて表示

EGFR アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (1)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Voacamine 関連分類

HY-N6932 関連分類